NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	$ 1,004,415	$ 883,015	$ 792,156
Clinical Trial and Manufacturing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	79,510	13,082	35,300
Clinical Trial and Manufacturing | Roche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	39,320	0	0
Clinical Trial and Manufacturing | Regeneron Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	38,220	12,926	24,989
Clinical Trial and Manufacturing | Other
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	1,970	156	10,311
External Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	8,963	2,820	1,615
External Services | Roche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	2,337	0	0
External Services | Regeneron Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	5,836	2,141	840
External Services | Other
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	790	679	775
Other
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	38,542	28,272	52,071
Other | Roche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	2,963	0	0
Other | Regeneron Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	33,388	27,935	47,582
Other | Other
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total research and development expenses	$ 2,191	$ 337	$ 4,489